HRT Financial’s Novavax NVAX Stock Holding History

HRT Financial’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,600	Closed	-$338K	–	3471
2022 Q1	$338K	Buy	+4,600	New	+$410K	﹤0.01%	2150
2021 Q1	–	Sell	-10,500	Closed	-$1.17M	–	3015
2020 Q4	$1.17M	Buy	+10,500	New	+$1.12M	0.02%	539

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial's NVAX Position: Q1 2026 in Review

HRT Financial sold out of Novavax (NVAX) in Q1 2026, closing a stake of 834,223 shares — an estimated $7.56M sold.

HRT Financial first reported a position in NVAX in Q2 2015 and held it in 16 quarters. The position peaked at $23.2M in Q2 2021. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

HRT Financial reported no remaining Novavax position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 834,223 Novavax shares in Q1 2026, an estimated $7.56M.
HRT Financial first reported a position in Novavax in Q2 2015 and held it in 16 quarters.
HRT Financial's Novavax position peaked at $23.2M in Q2 2021.
257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.